SpringWorks Therapeutics Competitors

QIAGEN (NYSE:QGEN) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Risk & Volatility

QIAGEN has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Valuation & Earnings

This table compares QIAGEN and SpringWorks Therapeutics' revenue, earnings per share (EPS) and valuation.

QIAGEN has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

43.6% of QIAGEN shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares QIAGEN and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for QIAGEN and SpringWorks Therapeutics, as reported by MarketBeat.com.

QIAGEN currently has a consensus price target of $60.76, suggesting a potential upside of 17.73%. SpringWorks Therapeutics has a consensus price target of $95.20, suggesting a potential upside of 28.70%. Given SpringWorks Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe SpringWorks Therapeutics is more favorable than QIAGEN.

Summary

QIAGEN beats SpringWorks Therapeutics on 8 of the 13 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Earnings & Valuation

This table compares SpringWorks Therapeutics and Repligen's top-line revenue, earnings per share and valuation.

Repligen has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SpringWorks Therapeutics and Repligen's net margins, return on equity and return on assets.

Risk & Volatility

SpringWorks Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Institutional and Insider Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for SpringWorks Therapeutics and Repligen, as reported by MarketBeat.com.

SpringWorks Therapeutics currently has a consensus target price of $95.20, indicating a potential upside of 28.70%. Repligen has a consensus target price of $219.00, indicating a potential upside of 4.98%. Given SpringWorks Therapeutics' higher probable upside, research analysts plainly believe SpringWorks Therapeutics is more favorable than Repligen.

Summary

Repligen beats SpringWorks Therapeutics on 10 of the 12 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Risk & Volatility

SpringWorks Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for SpringWorks Therapeutics and CRISPR Therapeutics, as reported by MarketBeat.

SpringWorks Therapeutics presently has a consensus target price of $95.20, indicating a potential upside of 28.70%. CRISPR Therapeutics has a consensus target price of $158.80, indicating a potential upside of 25.51%. Given SpringWorks Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SpringWorks Therapeutics is more favorable than CRISPR Therapeutics.

Insider and Institutional Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by insiders. Comparatively, 17.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares SpringWorks Therapeutics and CRISPR Therapeutics' gross revenue, earnings per share (EPS) and valuation.

CRISPR Therapeutics has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SpringWorks Therapeutics and CRISPR Therapeutics' net margins, return on equity and return on assets.

Summary

CRISPR Therapeutics beats SpringWorks Therapeutics on 8 of the 13 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Volatility & Risk

Neurocrine Biosciences has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Insider and Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Neurocrine Biosciences and SpringWorks Therapeutics' revenue, earnings per share (EPS) and valuation.

Neurocrine Biosciences has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neurocrine Biosciences and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Neurocrine Biosciences and SpringWorks Therapeutics, as provided by MarketBeat.com.

Neurocrine Biosciences currently has a consensus price target of $128.7222, suggesting a potential upside of 34.60%. SpringWorks Therapeutics has a consensus price target of $95.20, suggesting a potential upside of 28.70%. Given Neurocrine Biosciences' higher possible upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than SpringWorks Therapeutics.

Summary

Neurocrine Biosciences beats SpringWorks Therapeutics on 11 of the 13 factors compared between the two stocks.

Acceleron Pharma (NASDAQ:XLRN) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Risk & Volatility

Acceleron Pharma has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Valuation & Earnings

This table compares Acceleron Pharma and SpringWorks Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

SpringWorks Therapeutics has lower revenue, but higher earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Acceleron Pharma and SpringWorks Therapeutics, as reported by MarketBeat.

Acceleron Pharma currently has a consensus target price of $148.2143, indicating a potential upside of 19.45%. SpringWorks Therapeutics has a consensus target price of $95.20, indicating a potential upside of 28.70%. Given SpringWorks Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe SpringWorks Therapeutics is more favorable than Acceleron Pharma.

Insider and Institutional Ownership

79.8% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 2.5% of Acceleron Pharma shares are owned by company insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Acceleron Pharma and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Summary

SpringWorks Therapeutics beats Acceleron Pharma on 9 of the 14 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and Fate Therapeutics (NASDAQ:FATE) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Volatility & Risk

SpringWorks Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Insider and Institutional Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by insiders. Comparatively, 21.4% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares SpringWorks Therapeutics and Fate Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for SpringWorks Therapeutics and Fate Therapeutics, as provided by MarketBeat.

SpringWorks Therapeutics currently has a consensus target price of $95.20, suggesting a potential upside of 28.70%. Fate Therapeutics has a consensus target price of $108.3125, suggesting a potential upside of 25.89%. Given SpringWorks Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe SpringWorks Therapeutics is more favorable than Fate Therapeutics.

Valuation and Earnings

This table compares SpringWorks Therapeutics and Fate Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

SpringWorks Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

SpringWorks Therapeutics beats Fate Therapeutics on 8 of the 13 factors compared between the two stocks.